Who Supplies Dolutegravir to India from UNITED KINGDOM

Importing finished pharmaceutical formulations containing Dolutegravir into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs possess a valid import license. For formulations, a Form 10 license is necessary. The application process involves submitting detailed product information, including composition, manufacturing details, and evidence of safety and efficacy. The Drug Controller General of India (DCGI) evaluates these submissions, and upon approval, an import license is granted. The registration timeline can vary, but it typically spans several months, depending on the completeness of the application and regulatory workload. Specific requirements for Dolutegravir formulations under HS Code 30049099 include comprehensive documentation of the manufacturing process, quality control measures, and stability data. Additionally, a No Objection Certificate (NOC) from the manufacturer may be required to confirm the authenticity and quality of the product. It's crucial to ensure that all documentation is current and complies with CDSCO standards to facilitate a smooth import process.

Imported pharmaceutical formulations containing Dolutegravir must undergo quality testing to ensure they meet Indian standards. CDSCO-approved laboratories conduct batch-wise testing, which includes verifying the product's identity, purity, strength, and quality. A Certificate of Analysis (CoA) from the manufacturer is mandatory, detailing the product's specifications and testing results. Stability data, adhering to International Council for Harmonisation (ICH) guidelines for Zone IV conditions, is also required to demonstrate the product's shelf-life and efficacy under Indian climatic conditions. The Indian Pharmacopoeia standards serve as the benchmark for quality assessment. Upon arrival, customs drug inspectors perform port inspections to verify compliance with these standards. If a batch fails to meet the required criteria, it may be rejected, leading to potential delays and financial losses. Therefore, ensuring that all imported batches comply with CDSCO standards is essential for market acceptance.

Between 2024 and 2026, India has implemented several regulatory updates affecting pharmaceutical imports. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of finished formulation imports. Additionally, the CDSCO has streamlined procedures for drug registration and import licensing to enhance efficiency. Bilateral agreements between India and the United Kingdom have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which can expedite the approval process for UK-manufactured products. These developments aim to balance the promotion of domestic industry with the need for high-quality imported pharmaceuticals.

India imports finished Dolutegravir formulations to meet the demand for antiretroviral therapy (ART) in the treatment of HIV/AIDS. While domestic manufacturers produce Dolutegravir, imported formulations are often sought after for their brand recognition, perceived quality, and specific dosage forms not available locally. The market size for Dolutegravir in India is substantial, with a growing number of patients requiring ART. Imported formulations play a crucial role in supplementing domestic production to ensure a consistent and diverse supply of these essential medications.

The import duty structure for finished pharmaceutical formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%. A Social Welfare Surcharge (SWS) of 10% is levied on the BCD, resulting in an effective duty rate of 11%. Integrated Goods and Services Tax (IGST) is applicable as per prevailing rates, which can vary based on the product and its classification. There are no specific exemptions or concessional duties for imports from the United Kingdom under this HS code. Therefore, importers should account for these duties when calculating the total landed cost of goods.

India sources finished Dolutegravir formulations from the United Kingdom due to the UK's strong pharmaceutical manufacturing capabilities, adherence to stringent quality standards, and the availability of branded formulations. The UK's competitive advantage lies in its established patents, specialized dosage forms, and a reputation for high-quality products. While other suppliers, such as China, Germany, and the United States, also export Dolutegravir formulations to India, the UK's share remains significant due to these factors. The preference for UK-manufactured products is driven by the assurance of quality and compliance with international standards, which are critical in the pharmaceutical industry.

India imports finished Dolutegravir formulations from the United Kingdom to access branded products with established efficacy and safety profiles. The UK's advanced pharmaceutical manufacturing infrastructure and adherence to international quality standards make its products highly desirable. Specific formulations, such as certain dosage forms or combination therapies, may not be available from domestic manufacturers, necessitating imports to meet patient needs.

When compared to other origins like China, Germany, and the United States, the United Kingdom offers a competitive edge in terms of product quality, regulatory compliance, and brand recognition. While China may offer cost advantages, concerns about quality and regulatory standards can be a deterrent. Germany and the United States also provide high-quality products but may have higher costs or longer lead times. The United Kingdom's balance of quality, cost, and reliability positions it favorably in the Indian market.